Therapeutic role of EF24 targeting glucose transporter 1-mediated metabolism and metastasis in ovarian cancer cells

EF24, a novel curcumin analog, disrupts the microtubule cytoskeleton and inhibits HIF-1

(2014) Shala L. Thomas et al.   CELL CYCLE

An international assessment of ovarian cancer incidence and mortality

(2013) Kimberly A. Lowe et al.   GYNECOLOGIC ONCOLOGY

Protein profiles in human ovarian cancer cell lines correspond to their metabolic activity and to metabolic profiles of respective tumor xenografts

(2012) Christian Fabian et al.   FEBS Journal

Aberrant Expression of the Mammalian Target of Rapamycin, Hypoxia-inducible Factor-1α, and Glucose Transporter 1 in the Development of Ovarian Clear-cell Adenocarcinoma

(2012) Masafumi Kato et al.   INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY

Resistance of uveal melanoma to the interstrand cross-linking agent mitomycin C is associated with reduced expression of CYP450R

(2011) P Gravells et al.   BRITISH JOURNAL OF CANCER

Regulation of placenta growth factor by microRNA-125b in hepatocellular cancer

(2011) Gianfranco Alpini et al.   JOURNAL OF HEPATOLOGY

MUC4 mucin-induced epithelial to mesenchymal transition: a novel mechanism for metastasis of human ovarian cancer cells

(2010) M P Ponnusamy et al.   ONCOGENE

Glutaminase 2, a novel p53 target gene regulating energy metabolism and antioxidant function

(2010) W. Hu et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

GLUT1 Expression Is Increased in Hepatocellular Carcinoma and Promotes Tumorigenesis

(2009) Thomas Amann et al.   AMERICAN JOURNAL OF PATHOLOGY

GLUT1 as a therapeutic target in hepatocellular carcinoma

(2009) Thomas Amann et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth

(2008) Heather R. Christofk et al.   NATURE

Nutrient transporters in cancer: Relevance to Warburg hypothesis and beyond

(2008) Vadivel Ganapathy et al.   PHARMACOLOGY & THERAPEUTICS